Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Plummer, Elizabeth Ruth, Cook, Natalie , Melear, Jason M., Redfern, Charles H., Chung, Ki Y. , Haddad, Tufia C. , Goddemeier, Thomas, Arkenau, Hendrik‐Tobias , Spira, Alexander I. , Shapiro, Geoffrey I. , Ramalingam, Suresh S. , Wesolowski, Robert , Falk, Martin H., Dean, Emma

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e21048-e21048

10.1200/jco.2018.36.15_suppl.e21048 Get It

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).
Holstein, Sarah A. , Larkins, Gail, Chung, Weiyuan, Srinivasan, Shankar , Agarwal, Amit , Ailawadhi, Sikander , McCarthy, Philip L. , Lonial, Sagar

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8050-8050

10.1200/jco.2018.36.15_suppl.8050 Get It

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Barry, William T., Wenham, Robert M. , Hendrickson, Andrea E. Wahner , Armstrong, Deborah K. , Chan, Nancy , Lee, Jung‐Min , Penson, Richard T. , Cristea, Mihaela , Abbruzzese, James L. , Matsuo, Koji , Olawaiye, Alexander , Farooq, Sarah , Kohn, Elise C. , Matulonis, Ursula A. , Liu, Joyce F. , Cohn, David E. , Swisher, Elizabeth M. , Van Allen, Eliezer M , Shapiro, Geoffrey I. , Ivy, S. Percy

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5519-5519

10.1200/jco.2018.36.15_suppl.5519 Get It

A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
Vaishampayan, Ulka N. , Matrana, Marc , Zurita, Amado J. , Keam, Bhumsuk , Sundararajan, Srinath , Mowat, Rex B., Dudek, Arkadiusz Z. , Gan, Lu , Vaishampayan, Ulka , McDermott, David F. , Rha, Sun Young , Ho, Thai H. , Lee, Jae‐Lyun , Joseph, Richard W. , Ali, Sarah, Stadler, Walter M. , Haas, Naomi B , Park, Se Hoon , Picus, Joel , Zakharia, Yousef , Atkins, Michael B. , Dudek, Arkadiusz Z

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4510-4510

10.1200/jco.2018.36.15_suppl.4510 Get It

Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.
Shih, Kent C. , Patel, Manish R. , Butowski, Nicholas , Kizilbash, Sani H. , Bacha, Jeffrey , Brown, Dennis , Schwartz, Richard S. , Kanekal, Sarath, Constant, John C.I., Burris, Howard A. , Kizilbash, Sani H , Falchook, Gerald Steven , Jones, Suzanne Fields

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2061-2061

10.1200/jco.2018.36.15_suppl.2061 Get It

Combined single‐stage enterolysis with pedicle seromuscular bowel flaps, myocutaneous and fasciocutaneous flaps to repair recurrent enterocutaneous fistulas in complex abdominal Wall defects
Adabi, Kian , Vijayasekaran, Aparna , Moran, Steven L. , Ciudad, Pedro , Huang, Tony Chieh‐Ting , Nicoli, Fabio , Bishop, Sarah N. , Vijayasekaran, Aparna , Ciudad, Pedro , Huang, Tony C T , Bishop, Sarah , Chen, Hung‐Chi

Mayo Clinic

Microsurgery | September 4, 2018 | Volume: 40 | Issue: 1 | Pages: 19-24

10.1002/micr.30374 | PMID 30178520 Get It

AbstractIntroductionReconstruction of abdominal wall defects with enterocutaneous fistulas (ECF) remains challenging. The purpose of this report is to describe a single‐stage approach using combined microscopic enterolysis, pedicle seromuscular bowel flaps, mesh, fasciocutaneous, and myocutaneous flaps.MethodsBetween 1990 and 2016 a retrospective review identified a total of 18 patients with an average age of 39 years (ranging 26–59 years). Thirteen cases were associated with trauma, four were complication of previous mesh repair, and one was after an aortic dissection. Average diameter of defect size was 22 cm (ranging 20–24 cm). Surgical technique involved enterolysis using microscope magnification, a pedicle seromuscular bowel flap to reinforce the bowel anastomosis, mesh, musculocutaneous, and fasciocutaneous flaps to reconstruct the abdominal wall.ResultsFifteen patients required rotational flaps with an average skin paddle area of 442.7 cm2 (ranging 440 cm2–260 cm2) and 10 patients required a serosal patch with an average length of 5 cm (ranging 4–6 cm). Complications included three wound dehiscence and one abdominal wall bulging. Flap survival was 100%. The majority of patients (12 out of 18) were able to resume normal activities, and the remaining (n = 6) were able to resume most activities. Functional outcome as assessed by 36‐Item Short Form Survey (SF‐36) physical function component questionnaire at 18–24 months follow up was 67.8% (ranging from 59 to 72%). Mean length of hospital stay was 2.2 weeks (ranging 1.4–2.7 weeks). Mean follow‐up was 24 months (ranging 22–26 months) with clinical examination.ConclusionMicroscopically assisted intra‐abdominal dissection with resection of diseased bowel, replacement with well‐vascularized tissue at the anastomosis site in, and reinforcement with mesh combined with pedicle musculocutaneous and fasciocutaneous flaps may be an alternative when other local reconstructive options have failed.
Temporal lobe contusions on computed tomography are associated with impaired 6-month functional recovery after mild traumatic brain injury: a TRACK-TBI study
Yue, John K. , Winkler, Ethan A. , Puffer, Ross C. , Deng, Hansen , Wagle, Sagar, Morrissey, Molly Rose, Rivera, Ernesto J. , Runyon, Sarah J., Vassar, Mary J. , Taylor, Sabrina R. , Cnossen, Maryse C. , Lingsma, Hester F. , Yuh, Esther L. , Schnyer, David M. , Puccio, Ava M. , Valadka, Alex B. , Okonkwo, David O. , Manley, Geoffrey T. , Investigators, the TRACK-TBI, Schnyer, David M , Phelps, Ryan , Mukherjee, Pratik

Mayo Clinic

Neurological Research | September 3, 2018 | Volume: 40 | Issue: 11 | Pages: 972-981

10.1080/01616412.2018.1505416 | PMID 30175944 Get It

Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis
Moran, Sarah , Zgaga, Lina , Cuthbertson, David, Carette, Simon , Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Moreland, Larry W. , Sreih, Antoine G. , Ytterberg, Steven R. , Little, Mark A. , Cuthbertson, David , Moreland, Larry W , Monach, Paul A. , Khalidi, Nader , Pagnoux, Christian , Seo, Philip , Specks, Ulrich , Wyse, Jason , Merkel, Peter A.

Mayo Clinic

Nephrology Dialysis Transplantation | September 1, 2018 | Volume: 35 | Issue: 2 | Pages: 283-291

10.1093/ndt/gfy300 | PMID 30380100 Get It

Abstract Background Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples that included new diagnoses with highly active renal disease. This study focused on the use of usCD163 in the detection of the more clinically relevant state of mild renal flare and compared results of usCD163 testing directly to testing of urinary monocyte chemoattractant protein-1 (uMCP-1). Methods Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV, n = 88) were identified within a serially sampled, longitudinal and multicentre cohort. Creatinine-normalized usCD163 and uMCP-1 levels were measured by enzyme-linked immunosorbent assay and, both alone and in combination, were compared between times of active renal AAV and during remission and/or active non-renal AAV. Results Samples from 320 study visits included times of active renal vasculitis (n = 39), remission (n = 233) and active extrarenal vasculitis (n = 48). Median creatinine levels were 0.9 mg/dL [interquartile range (IQR) 0.8–1.2] in remission and 1.4 mg/dL (IQR 1.0–1.8) during renal flare. usCD163 levels were higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 162 ng/mmol (IQR 79–337), 44 (17–104) and 38 (7–76), respectively (P < 0.001). uMCP-1 levels were also higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 10.6 pg/mmol (IQR 4.6–23.5), 4.1 (2.5–8.4) and 4.1 (1.9–6.8), respectively (P < 0.001). The proposed diagnostic cut-points for usCD163 and uMCP-1 were 72.9 ng/mmol and 10.0 pg/mmol, respectively. usCD163 and uMCP-1 levels were marginally correlated (r2 = 0.11, P < 0.001). Combining novel and existing biomarkers using recursive tree partitioning indicated that elevated usCD163 plus either elevated uMCP-1 or new/worse proteinuria improved the positive likelihood ratio (PLR) of active renal vasculitis to 19.2. Conclusion A combination of usCD163 and uMCP-1 measurements appears to be useful in identifying the diagnosis of subtle renal vasculitis flare.
Parenteral phenobarbital in status epilepticus revisited: Mayo Clinic experience
Hocker, Sara E. , Clark, Sarah L. , Hocker, Sara, Clark, Sarah, Britton, Jeffrey, Britton, Jeffrey W.

Mayo Clinic

Epilepsia | August 30, 2018 | Volume: 59 | Issue: S2 | Pages: 193-197

10.1111/epi.14488 | PMID 30159873 Get It

SummaryDespite phenobarbital (PB) being a key component in status epilepticus (SE) treatment algorithms for decades, it has fallen out of favor compared to newer nonsedating medications due to potential for respiratory suppression and prolonged sedation. We retrospectively analyzed all nonintubated patients with refractory SE treated with parenteral PB. Forty patients were identified as having received PB in the neurologic intensive care unit at Mayo Clinic over a 7‐year period through our pharmacy dispensing database. Patients who received PB for maintenance therapy, those replenishing subtherapeutic levels, those who were already intubated, and those receiving PB for a non‐SE indication were excluded. Clinical data, prior treatments, therapeutic response, and outcome were reviewed. Eight patients were identified. Ages ranged from 24 to 77 years (median = 64 years); all had focal SE, and none was comatose. Seizure activity improved acutely following PB administration in seven and stopped in six. Dosages ranged from 5 to 19.8 mg/kg (median = 10.1 mg/kg); none required intubation, and one received supplemental oxygen. Patients received a median of four antiepileptic drugs prior to PB. Median interval between first drug and PB was 23.5 hours. Glasgow Coma Scale score did not change following PB administration. One patient required intervention for hypotension. Moderate‐dose parenteral PB was effective in attaining seizure control in a significant proportion of noncomatose refractory SE patients. None required ventilatory support. PB dosages below those in recent guidelines may be sufficient to stop SE without clinically significant cardiopulmonary complications.
Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al‐Bawardy, Badr , Ramos, Guilherme Piovezani , Jenkins, Sarah M. , Park, Sang Hyoung , Schoenoff, Shayla, Bruining, David H. , Papadakis, Konstantinos A. , Raffals, Laura E. , Tremaine, William J., Loftus, Edward V. , Aniwan, Satimai , Schoenoff, Shayla A, Raffals, Laura, Loftus, Edward V , Ramos, Guilherme P , Willrich, Maria Alice V.

Mayo Clinic

Inflammatory Bowel Diseases | August 24, 2018 | Volume: 25 | Issue: 3 | Pages: 580-586

10.1093/ibd/izy272 | PMID 30165638 Get It